Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
P39086
UPID:
GRIK1_HUMAN
Alternative names:
Excitatory amino acid receptor 3; Glutamate receptor 5
Alternative UPACC:
P39086; Q13001; Q86SU9
Background:
The Glutamate receptor ionotropic, kainate 1, also known as Excitatory amino acid receptor 3 or Glutamate receptor 5, plays a pivotal role in neurotransmission. It acts as an ionotropic glutamate receptor, where L-glutamate serves as an excitatory neurotransmitter in the central nervous system. Upon L-glutamate binding, the receptor undergoes a conformational change, opening the cation channel and converting the chemical signal into an electrical impulse.
Therapeutic significance:
Understanding the role of Glutamate receptor ionotropic, kainate 1 could open doors to potential therapeutic strategies.